GPT and metabolic dysfunction-associated steatotic liver disease: Subjects in ALT Q2 (adjusted OR = 1.62, 95% CI [1.21–2.17]), Q3 (adjusted OR = 3.03, 95% CI [2.26–4.05]) and Q4 (adjusted OR = 4.83, 95% CI [3.57–6.52]) had significantly increased risk of NAFLD compared to Q1 after adjusted for gender, age, BMI, SBP and DBP (Ptrend < 0.001).